The medical and financial complications associated with nosocomial infections have had a significant impact on hospitals, particularly in the current era of fiscal constraints (4, 5, 11) . Efforts to decrease the frequency of these infections have included implementation of infection surveillance programs and strict adherence to accepted infection control practices, including handwashing and the use of protective gowns, masks, and gloves when appropriate. Although these practices have been demonstrated to be effective controls, the success of infection control practices requires compliance by medical personnel. For example, if protective gowns are not worn or if they are not changed between contact with patients, nosocomial pathogens can be transferred from the bedding of one patient to the clothing of the medical personnel and then to the bedding of a subsequent patient (1, 3, 7, 10) . Although this transfer can be prevented by changing gowns between patients, this practice is difficult to enforce. An alternative method is to treat the clothing with an antimicrobial factor that will kill organisms that come into contact with the fabric. Such a fabric has been developed for this purpose by Burlington Industries (Burlington, Vt.) and is currently marketed by Medline Industries under the tradename BioGuard.
The cotton-polyester fabric is treated with 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride, which was developed by Dow Corning Corp. (Midland, Mich.) under the product name 5700 Antimicrobial Agent (DC 5700) (8) . DC 5700 is a quaternary ammonium compound that is bound irreversibly to the fabric by the trimethoxysilyl propyl coupling agent, which prevents the loss of antimicrobial activity after repeated washings of the garments (6) . In vivo studies with laparotomy drapes treated with DC 5700 demonstrated a significant decrease (average, 84.4%) in the recovery of viable bacteria when compared with nontreated fabric (2) . However, gram-negative bacilli were infrequently recovered from either DC 5700-treated or untreated fabric, so the effectiveness of the compound against either these bacteria or fungi could not be evaluated.
In this study we evaluated the efficacy of the antimicrobial activity of DC 5700 against bacterial and fungal organisms commonly isolated in the hospital environment. Test fabric. Untreated cotton-polyester fabric and fabric treated with DC 5700 (BioGuard fabric) was provided by Medline Industries. The concentration of DC 5700 in the BioGuard fabric is proprietary information, so additional fabric was treated by Dow Corning Corp. with six concentrations of DC 5700 ranging from 0.03 to 1.0%. This fabric was used to determine the antimicrobial activity of various concentrations of DC 5700 on selected microbial pathogens.
Agar overlay bioassay. Individual isolates were adjusted to a turbidity equivalent to a McFarland 0.5 standard, added to melted tryptic soy agar (final concentration, 106 CFU/ml), and the poured into a petri dish with either the treated or untreated fabric. After the agar solidified, the plates were incubated overnight at 35°C in a 5% C02 incubator. Microbial growth in the petri dishes was examined; inhibition of growth at the edge of the fabric and in the agar overlaying the material was considered representative of significant antimicrobial activity (see Fig. 1 Pseudomonas aeruginosa, and Candida albicans) were not inhibited by fabric treated with any concentration of DC 5700.
Because DC 5700 is irreversibly bound to the fabric, the agar overlay bioassay may not detect weak inhibition of organisms in direct contact with the fabric. Indeed, Dow Corning has dismissed agar overlay testing as invalid and recommends the use of fabric testing in broth cultures (R. Gettings, personal communication). The continual mixing of the culture in this method allows greater contact of the test organisms with the fabric surface. We performed a broth agitation experiment with three quality control organisms (S. aureus ATCC 25923, E. coli ATCC 25922, and P. aeruginosa ATCC 27853) commonly used in clinical microbiology laboratories. After 4 h of exposure to the commercially prepared Bioguard fabric, S. aureus ATCC 25923 was significantly inhibited, with a greater than 10,000-fold reduction in viable counts. In contrast, no inhibition of the two gram-negative bacilli was observed at 4 h. Identical results were observed with these three organisms after 24 h of incubation.
Discussion. The results of this study demonstrate that fabric treated with DC 5700 is an effective inhibitor of most gram-positive cocci. However, we were unable to demonstrate antimicrobial activity against virtually all gram-negative bacilli or yeasts tested by either the agar overlay bioassay or the broth agitation assay. These results are in contrast with the manufacturer's claim that BioGuard fabric reduces bacterial counts on contaminated material by more than 95% (12) . An explanation for this disparity is not readily apparent. Although quaternary ammonium compounds have bactericidal and fungicidal activity, they generally have greatest activity against gram-positive bacteria (9) . Consistent with this fact, White and Gettings (12) reported the DC 5700 MICs were 10 ±Lg/ml for Streptococcusfaecalis, 100 p.g/ ml for E. coli and P. aeruginosa, and 1,000 ptg/ml for Aspergillus niger. The relevance of this observation is unclear because the compound was tested in solution rather than bonded to fabric. For that reason, we tested fabric treated with a range of DC 5700 concentrations (0.05 to 1.0%). Unfortunately, we were unable to demonstrate any activity against gram-negative bacilli or yeasts. Higher concentrations of DC 5700 might be inhibitory, but we were unable to test these. The concentration of DC 5700 used to treat the BioGuard fabric and the method of treatment were not available from the manufacturer. Therefore, it is unknown if the fabric was prepared in the same manner that was previously demonstrated to produce activity against gram-negative bacilli.
In summary, BioGuard fabric has limited value in reducing bacterial contamination of medical personnel clothing and surgical drapes. We encourage the manufacturer to continue efforts to develop a fabric with antimicrobial properties. This could be accomplished by either testing higher concentrations of DC 5700 for activity against all microbes or evaluating alternative quaternary ammonium compounds with better activity against gram-negative bacilli and yeasts.
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